Sunday, June 14 – For those scared of needles but who need GLP-1 receptor agonists to help manage their weight, there might be some good news. Researchers are testing a new oral, small-molecule GLP-1 receptor agonist called Elecoglipron, which could offer the weight-loss benefits of GLP-1 therapy without injections.

Sunday, June 14 – Northwestern Medicine scientists have identified a safety concern associated with GLP-1 drugs. Using health record data, the research team tracked more than 42,000 adults already taking at least two types of blood pressure medications. After starting GLP-1s, these patients experienced higher rates of dizziness, fainting and other events related to low blood pressure, also known as hypotension.

Saturday, June 18 – Survodutide weight-loss drug may reduce harmful fat while preserving muscle.

Saturday, June 18 – Recent research has found that despite the benefits, people using GLP-1s may be less likely to exercise. Image Credit: Fiordaliso/Getty Images

A recent study found that people taking a GLP-1 medication, like Ozempic or Wegovy, may be less likely to engage in regular exercise. 

The study showed that, among people with obesity, daily step count and moderate-to-vigorous activity duration decreased after starting GLP-1 medication.

Saturday, June 18 – Once-weekly cagrilintide, an amylin receptor agonist, plus semaglutide is efficacious for adults with type 2 diabetes inadequately controlled with diet and exercise, receiving metformin with or without a sodium glucose cotransporter 2 inhibitor (SGLT2i), and using basal insulin, according to three studies published online June 7 in The Lancet Diabetes & Endocrinology and The Lancet to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans.

FRIDAY, June 12, 2026 — Once-weekly cagrilintide, an amylin receptor agonist, plus semaglutide is efficacious for adults with type 2 diabetes inadequately controlled with diet and exercise, receiving metformin with or without a sodium glucose…

Friday, June 12 – For adults with obesity but without diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a significantly lower short-term incidence of obesity-associated cancers (OACs), according to a…

THURSDAY, June 11, 2026 — For adults with obesity but without diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a significantly lower short-term incidence of obesity-associated cancers (OACs), according to a study…

Friday, June 12 – Regulator approval means patients who meet criteria will be able to purchase tablets with private prescription Patients in the UK will soon be able to buy the Wegovy weight-loss pill, the medicines regulator announced on Thursday.It is the first GLP-1 receptor agonist tablet for weight-loss to be approved by the Medicines and Healthcare products Regulatory Agency (MHRA), making the UK the third country to authorise the pills, behind the US and the United Arab Emirates. Continue reading…

Friday, June 12 – Manufacturer Novo Nordisk says a daily tablet of the drug could be more convenient for some people than weekly injections.

Friday, June 12 – Researchers from Verdiva Bio Ltd. and collaborators recently presented preclinical data on VRB-103, an oral amylin analogue, comparing its profile with those of cagrilintide and eloralintide, two subcutaneously administered analogues currently in clinical development.

Thursday, June 11 – Customers have complained that a telehealth network selling compounded GLP-1s has been ripping them off—even after it had to pay $5 million to clients as part of a settlement with the US government.

Thursday, June 11 – New oral GLP-1 drug lowers blood sugar levels by 7% in people with type 2 diabetes.

Thursday, June 11 – NEW YORK, NEW YORK – MAY 12: Shaquille O’Neal attends the 2026 Disney Upfront at Jacob K. Javits Convention Center on May 12, 2026 in New York City. (Photo by John Nacion/FilmMagic)

Shaquille O’Neal is taking Zepbound to help manage his weight and reduce obstructive sleep apnea (OSA) symptoms.

Zepbound is FDA approved for moderate to severe OSA in adults living with obesity.

Excess weight, especially around the neck, can worsen OSA symptoms by narrowing the airway and increasing the risk of collapse during sleep.

AstraZeneca News Release, June 8, 2026 —

11.8% weight loss achieved at 36 weeks in adults with obesity or overweight in the VISTA Phase IIb trial
HbA1c lowered by 1.9% at 26 weeks in adults with type 2 diabetes in the SOLSTICE Phase IIb…

Thursday, June 11 – For adults with obesity without diabetes, once-weekly survodutide, an investigational glucagon receptor-glucagon-like peptide-1 receptor dual agonist, is associated with greater reductions in body weight than placebo, according to a study published online June 7 in the New England Journal of Medicine to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans.

WEDNESDAY, June 10, 2026 — Continuation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) into early pregnancy seems not to be associated with the risk for nonlive birth, abnormal fetal growth, or major congenital malformation (MCM)…

WEDNESDAY, June 10, 2026 — For adults with type 2 diabetes (T2D) that is inadequately controlled with diet and exercise alone, retatrutide, a triple hormone receptor agonist, is associated with significant improvements in glycemic control and body…

WEDNESDAY, June 10, 2026 — For adults with obesity without diabetes, once-weekly survodutide, an investigational glucagon receptor-glucagon-like peptide-1 receptor dual agonist, is associated with greater reductions in body weight than placebo…

Thursday, June 11 – A D.C. federal judge Wednesday agreed to toss a proposed class action against CVS Caremark and CareFirst BlueCross BlueShield from a worker who challenged coverage denials for Zepbound to treat sleep apnea, holding an exclusion in his employee health plan that the companies administered complied with federal benefits law.

WEDNESDAY, June 10, 2026 — For patients with knee osteoarthritis (OA), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced long-term risk for total knee arthroplasty (TKA), according to a study published online June…

Thursday, June 11 – People across the Black diaspora are increasingly turning to weight-loss drugs. How might this reshape our health, wellbeing and body image?Don’t get The Long Wave delivered to your inbox? Sign up hereThese days, I barely make it through the week without seeing news about what weight-loss medications, such as Ozempic and Mounjaro, can now supposedly achieve.

Thursday, June 11 – Researchers at the University of Colorado Anschutz have published a proof-of-concept study in Fertility and Sterility demonstrating that injectable semaglutide may offer meaningful reproductive benefits for women with polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS).

WEDNESDAY, June 10, 2026 — Another GLP-1 pill could be headed for the market soon, according to early clinical trial results.
The once-daily experimental pill elecoglipron helped people control their blood sugar and lose weight in a pair of…

Wednesday, May 10 – GLP-1 drugs like Ozempic, Wegovy may help slow biological aging.

Wednesday, May 10 – AstraZeneca’s new oral GLP-1 pill showed promising results for weight loss and blood sugar in a phase 2 trial. Guido Mieth/Getty Images

A new GLP-1 oral medication from AstraZeneca, known as elecoglipron, lowered blood sugar levels and led to 10.5% weight loss in a phase 2b clinical trial.

Experts say GLP-1 drugs in tablet form may encourage more people to take these medications to help treat type 2 diabetes and obesity.

Wednesday, June 10 – (MedPage Today) — Investigational apitegromab — a selective myostatin activation inhibitor — effectively preserved lean mass when combined with tirzepatide (Zepbound) in a randomized phase II trial, suggesting it could help fight “Ozempic…

Wednesday, May 10 – GLP-1 receptor agonists remained center stage at the 2026 Scientific Sessions of the American Diabetes Association with Boehringer Ingelheim GmbH and Astrazeneca plc, joining the leaders, Eli Lilly and Co. and Novo Nordisk A/S, in presenting data for their respective GLP-1 drugs.

Wednesday, May 10 – TUESDAY, June 9, 2026 — For adults with type 2 diabetes and chronic kidney disease, two years of semaglutide treatment improves health-related quality of life (QoL) versus placebo, according to a study presented at the annual congress of the…

Wednesday, May 10 – Over the past few years, GLP-1 drugs have transformed the treatment landscape for obesity and type 2 diabetes. By mimicking a hormone that helps regulate blood sugar, slows digestion and curbs appetite, these medications have helped millions lose weight while improving metabolic health.

Wednesday, May 10 – (MedPage Today) — Note that some links may require registration or subscription.
Only 50% of the public said they now trust health recommendations from the CDC, down from 77% in spring 2025, according to a poll conducted by the Harvard School…

Wednesday, May 10 – Rivus Pharmaceuticals’ CEO Jorge Bartolome said the biotech is on track to build a “truly differentiated” cardiometabolic portfolio.

TUESDAY, June 9, 2026 — New research is shedding light on first-trimester GLP-1 exposure during pregnancy — and the findings may offer some reassurance.
GLP-1 use among women of reproductive age is increasing. And while current…

Wednesday, May 10 – AstraZeneca is pushing its small molecule GLP-1 drug to Phase 3 development for weight control, diabetes and other cardiometabolic conditions despite the asset failing to best one from Structure Therapeutics.

Wednesday, May 10 – Newly approved weight loss pill Foundayo reduced blood sugar more than Novo Nordisk’s semaglutide and other comparators in multiple Phase 3 type 2 diabetes trials. Eli Lilly will seek approval in this indication.

Wednesday, May 10 – Researchers believe the popular medication should be further studied as a cancer prevention tool.

Tuesday, June 9 – (MedPage Today) — NEW ORLEANS — Treatment with survodutide led to significant weight loss and reductions in liver fat in phase III trials of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), but about a fifth of…

Tuesday, June 9 – A target trial emulation estimated the risks associated with glucagon-like peptide-1 receptor agonist (GLP-1RA) exposure in early pregnancy. The findings did not indicate a substantially increased risk for nonlive birth, abnormal fetal growth, or major congenital malformation with continuation of GLP-1RAs into the first trimester.

Tuesday, June 9 – Oral GLP-1 medications have the potential to increase access to therapies that can help lower blood sugar and reduce bodyweight. At the American Diabetes Association’s Scientific Session, Mass General Brigham physician investigator Vanita Aroda, MD, presented findings from SOLSTICE, a Phase IIb randomized, placebo-controlled clinical trial that tested the oral GLP-1 RA known as elecoglipron.

Tuesday, June 9 – AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.